Actinogen Medical Limited (ACW.AX)

AUD 0.03

(-3.85%)

Market Cap (In AUD)

78.32 Million

Revenue (In AUD)

9.93 Million

Net Income (In AUD)

-13.04 Million

Avg. Volume

16.6 Million

Currency
AUD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.02-0.099
PE
-
EPS
-
Beta Value
1.23
ISIN
AU000000ACW3
CUSIP
Q0094Y104
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Steven G. Gourlay ), FRACP, M.B.A., MBBS (M.D., Ph.D.
Employee Count
-
Website
https://www.actinogen.com.au
Ipo Date
2007-10-16
Details
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It is developing Xanamem, an inhibitor of the 11ß-HSD1 enzyme, which is in Phase 2 clinical trials that achieves target engagement in the central nervous system, Alzheimer's disease, depression with cognitive impairment, and anxiety, sleep, and behavioral problems in fragile X syndrome. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.